FLT3 and leukemia: However, they were not all classified as intermediate risk group, as further genetic refinement of the patients genetic profile like NPM1, FLT3-ITD and C-KIT mutations changed patients classification from intermediate risk 33/70 (47.1%) to either low risk 24/70 (34.4%) (including 9 patients with CBF leukemia and 15 patients with NPM1 mutant) or high risk groups 13/70 (18.6%) patients (including 12 patients with FLT3-ITD mutant and one patient with -7).